Bastide Le Confort Medical

In-line FY24/25 underlying results; smooth deleveraging

27/10/25 -"Bastide’s FY24/25 underlying results aligned with guidance and our estimates. However, operational improvements were offset by significant non-recurring costs, primarily related to disposals, ..."

PDF page sample
Pages
50
Language
English
Published on
27/10/25
Download
You may also be interested by these reports :
27/10/25
Getinge reported a robust third quarter, with organic sales up 9.5% and adjusted EBITA rising 19%, translating to a 160bps margin expansion to 13.1% ...
27/10/25
Bastide’s FY24/25 underlying results aligned with guidance and our estimates. However, operational improvements were offset by significant ...
23/10/25
Sartorius Stedim Biotech reported an estimate-beating Q3 2025. Revenue was up 12.0%, driven almost entirely by the high-margin consumables business. ...
22/10/25
Sartorius delivered a robust Q3 2025 performance, beating consensus on both revenue and EBITDA, though slightly missing our EBITDA estimate. Revenue ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO